stockrowAmgen Inc.
AMGN Healthcare Drug Manufacturers General
Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024.
- Revenue
- +8.45%
- EPS
- +19.4%
- Free cash flow
- −0.16%
- Total debt
- −1.06%
Quarter to September 2026, against a year earlier
Follow AMGN
Alert me
Amgen Inc. (AMGN) Return on invested capital
Amgen Inc.'s return on invested capital over the twelve months to 30 September 2026 was 14.3%, up 3.8 percentage points from fiscal 2025 (10.5%). Over the past ten years it has ranged from 8.24% (fiscal 2023) to 37.5% (fiscal 2018); the current reading is higher than 27% of that period. That is above the Drug Manufacturers General industry median of 6.26% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 10.5% | 2.08 |
| FY2024 | 8.40% | 0.16 |
| FY2023 | 8.24% | (9.71) |
| FY2022 | 18.0% | 3.02 |
| FY2021 | 14.9% | (3.06) |
| FY2020 | 18.0% | (1.73) |
| FY2019 | 19.7% | (17.74) |
| FY2018 | 37.5% | 4.49 |
| FY2017 | 33.0% | 9.77 |
| FY2016 | 23.2% | 4.38 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVO Novo Nordisk A/S compare | 28.7% |
| ABBV AbbVie Inc. compare | 20.2% |
| AMGN Amgen Inc. | 14.3% |
| BMY Bristol Myers Squibb Company compare | 13.2% |
| AZN AstraZeneca PLC compare | 12.3% |
| NVS Novartis AG compare | 12.1% |
| PFE Pfizer Inc. compare | 6.19% |
| MRK Merck & Co., Inc. compare | 0.00% |
| GILD Gilead Sciences, Inc. compare | −4.51% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on AMGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement